Dr. Eber Discusses Patient Selection for Cytoreductive Nephrectomy in mRCC

Paul Eber, MD
Published: Thursday, Jan 17, 2019



Paul Eber, MD, urologist, The Conrad Pearson Clinic, discusses patient selection for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma (mRCC).

The ideal candidates for surgery, Eber says, are the patients with what appears to be an easily resectable tumor and very low-volume metastatic disease. Medical oncologists and urologists would both agree that these patients would derive the most benefit from nephrectomy followed by targeted therapy. Eber adds that ongoing studies in this space will hopefully clarify this question even more; however, in the meantime, urologists should always seek a second opinion from a medical oncologist on which route to take.

Community oncologists hoped that the CARMENA trial would help distinguish between this traditional procedure and the role of VEGF TKIs. Instead, the results led to more questions for physicians. The phase III trial showed that the addition of cytoreductive nephrectomy to sunitinib (Sutent) did not provide a survival benefit in patients with intermediate- and high-risk mRCC. Results showed that the median overall survival was 18.4 months and 13.9 months for patients who received sunitinib alone compared with surgery followed by targeted therapy, respectively.
SELECTED
LANGUAGE


Paul Eber, MD, urologist, The Conrad Pearson Clinic, discusses patient selection for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma (mRCC).

The ideal candidates for surgery, Eber says, are the patients with what appears to be an easily resectable tumor and very low-volume metastatic disease. Medical oncologists and urologists would both agree that these patients would derive the most benefit from nephrectomy followed by targeted therapy. Eber adds that ongoing studies in this space will hopefully clarify this question even more; however, in the meantime, urologists should always seek a second opinion from a medical oncologist on which route to take.

Community oncologists hoped that the CARMENA trial would help distinguish between this traditional procedure and the role of VEGF TKIs. Instead, the results led to more questions for physicians. The phase III trial showed that the addition of cytoreductive nephrectomy to sunitinib (Sutent) did not provide a survival benefit in patients with intermediate- and high-risk mRCC. Results showed that the median overall survival was 18.4 months and 13.9 months for patients who received sunitinib alone compared with surgery followed by targeted therapy, respectively.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x